The robust enhancement in dlPFC delay-related firing and d’ measures of spatial representation following local GCPII inhibition also indicate that GCPII inhibitors have great therapeutic potential for treating PFC cognitive disorders, and may be particularly useful in those with an inflammatory etiology, as described below. The gene discussed is FOLH1; the disease is cognitive disorder.